+ +

•  

   

     Western blot analysis using APOA4 mouse mAb against human serum (1), human plasma (2), HepG2 cell lysate (3) and SMMC-7721 cell lysate (4).    

  
  

The mitochondrial translation initiation factor 2 (MTIF2), also known as IF2mt, is a critical protein involved in initiating protein synthesis within mitochondria. It facilitates the assembly of the mitochondrial ribosome by binding to the small subunit (28S) and recruiting the initiator tRNA (fMet-tRNA) to start translation. MTIF2 is essential for the synthesis of mitochondrial DNA-encoded proteins, particularly components of the electron transport chain (ETC) complexes crucial for oxidative phosphorylation and cellular energy production. Structurally, it contains GTP-binding domains and interacts with mitochondrial ribosomes in a GTP-dependent manner.

Antibodies targeting MTIF2 are valuable tools for studying mitochondrial translation mechanisms, mitochondrial dysfunction, and associated diseases. Dysregulation of MTIF2 has been linked to disorders such as mitochondrial encephalopathies, cardiomyopathies, and cancer, where impaired energy metabolism plays a role. Researchers use MTIF2 antibodies in techniques like Western blotting, immunofluorescence, and immunoprecipitation to assess protein expression, localization, and interactions in cellular or tissue samples. These studies help elucidate how mitochondrial translation defects contribute to pathological conditions, offering potential insights for therapeutic strategies targeting mitochondrial protein synthesis. Commercial MTIF2 antibodies are typically validated for specificity using knockout controls or siRNA-based knockdowns.